Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China May Modify Single-Pricing Policy For Off-Patent Drugs

This article was originally published in PharmAsia News

Executive Summary

China's National Development and Reform Commission has requested related organizations to conduct a special investigation on the pricing and application quantity of off-patent drugs and generics, showing NDRC's intention to narrow the huge gap between both types of drugs. China's price policy allows off-patent drugs to enjoy a premium of 35 and 30 percent over GMP-produced generic injections and other formulations, respectively. However, industry sources disclose that off-patent drugs, of which overseas firms and joint ventures have the lion's share, are actually double to triple the price of generics. Many local pharmaceutical manufacturers accuse the policy of giving preferential treatment to foreign companies and joint ventures, at the expense of domestic enterprises. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts